Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models

Veterinary Parasitology

Volumn 187, Issue 1-2, 2012, Pages 44-52

  Barbosa, Bellisa Freitas ^a   Gomes, Angelica Oliveira ^a   Ferro, Eloisa Amália Vieira ^a   Napolitano, Danielle Reis ^a   Mineo, José Roberto ^a   Silva, Neide Maria ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Acquired toxoplasmosis; Calomys callosus; Chemotherapy; Enrofloxacin; Toxoplasma gondii

Indexed keywords

ENROFLOXACIN; PENICILLIN G; PYRIMETHAMINE; STREPTOMYCIN; SULFADIAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARASITE LOAD; PARASITE VIRULENCE; TOXOPLASMOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; FEMALE; FIBROBLASTS; FLUOROQUINOLONES; HUMANS; SIGMODONTINAE; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

ANIMALIA; CALOMYS CALLOSUS; NEOSPORA CANINUM; PROTOZOA; TOXOPLASMA GONDII;

EID: 84860666014     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2011.12.039     Document Type: Article

References (34)

1. Alves C.F., Vitor R.W. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil. Parasite 2005, 12:171-177.
2. Anderson A.C. Targeting DHFR in parasitic protozoa. Drug Discov. Today 2005, 10:121-128.
3. Barbosa B.F., Silva D.A.O., Costa I.N., Pena J.D.O., Mineo J.R., Ferro E.A.V. Susceptibility to vertical transmission of Toxoplasma gondii is temporally dependent on the preconceptional infection in Calomys callosus. Placenta 2007, 28:624-630.
4. Biswas S., Maggi R.G., Papich M.G., Keil D., Breitschwerdt E.B. Comparative activity of pradofloxacin, enrofloxacin, and azithromycin against Bartonella henselae isolates collected from cats and a human. J. Clin. Microbiol. 2010, 48:617-618.
5. Bohne W., Holpert M., Gross U. Stage differentiation of the protozoan parasite Toxoplasma gondii. Immunobiology 1999, 201:248-254.
6. Costa I.N., Angeloni M.B., Santana L.A., Barbosa B.F., Silva M.C.P., Rodrigues A.A., Rostkowsa C., Magalhães P.M., Pena J.D.O., Silva D.A.O., Mineo J.R., Ferro E.A.V. Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). Placenta 2009, 30:884-890.
7. Dantas-Leite L., Urbina J.A., de Souza W., Vommaro R.C. Selective anti-Toxoplasma gondii activities of azasterols. Int. J. Antimicrob. Agents 2004, 23:620-626.
8. Daubener W., Remscheid C., Nockemann S., Pilz K., Seghrouchni S., Mackenzie C., Hadding U. Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-γ and tumor necrosis factor-α. Eur. J. Immunol. 1996, 26:487-492.
9. Degerli K., Kilimcioglu A.A., Kurt O., Tamay A.T., Ozbilgin A. Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey. Acta Trop. 2003, 88:45-50.
10. Delespaux V., Vitouley H.S., Marcotty T., Speybroeck N., Berkvens D., Roy K., Geerts S., Van den Bossche P. Chemosensitization of Trypanosoma congolense strains resistant to isometamidium chloride by tetracyclines and enrofloxacin. PLoS Negl. Trop. Dis. 2010, 4:e828.
11. Elmas M., Uney K., Yazar E., Karabacak A., Tras B. Pharmacokinetics of enrofloxacin following intravenous and intramuscular administration in Angora rabbits. Res. Vet. Sci. 2007, 82:242-245.
12. Ferreira M.S., Borges A.S. Some aspects of protozoan infections in immunocompromised patients-a review. Mem. Inst. Oswaldo Cruz 2002, 97:443-457.
13. Ferreira R.A., Oliveira A.B., Ribeiro M.F., Tafuri W.L., Vitor R.W. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine. Exp. Parasitol. 2006, 113:125-129.
14. Ferro E.A.V., Silva D.A.O., Bevilacqua E., Mineo J.R. Effect of Toxoplasma gondii infection kinetics on trophoblast cell population in Calomys callosus, a model of congenital toxoplasmosis. Infect. Immun. 2002, 70:7089-7094.
15. Filisetti D., Candolfi E. Immune response to Toxoplasma gondii. Ann. Ist. Super Sanità 2004, 40:71-80.
16. Franco P.S., Silva D.A.O., Costa I.N., Gomes A.O., Silva A.L., Pena J.D.O., Mineo J.R., Ferro E.A.V. Evaluation of vertical transmission of Toxoplasma gondii in Calomys callosus model after reinfection with heterologous and virulent strain. Placenta 2011, 32:116-120.
17. Gazzinelli R.T., Wysocka M., Hieny S., Scharton Kersten T., Cheever A., Kuhn R., Muller W., Trinchieri G., Sher A. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J. Immunol. 1996, 157:798-805.
18. González C., Moreno L., Fumuso E., García J., Rivulgo M., Confalonieri A., Sparo M., Sánchez Bruni S. Enrofloxacin-based therapeutic strategy for the prevention of endometritis in susceptible mares. J. Vet. Pharmacol. Therap. 2010, 33:287-294.
19. Gottstein B., Razmi G.R., Ammann P., Sager H., Muller N. Toltrazuril treatment to control diaplacental Neospora caninum transmission in experimentally infected pregnant mice. Parasitology 2005, 130:41-48.
20. Govendir M., Hansen T., Kimble B., Norris J.M., Baral R.M., Wigney D.I., Gottlieb S., Malik R. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin. Vet. Microbiol. 2011, 147:113-118.
21. Jones J.L., Lopez A., Wilson M., Schulkin J., Gibbs R. Congenital toxoplasmosis: a review. Obstet. Gynecol. Surv. 2001, 56:296-305.
22. Kim K., Weiss L.M. Toxoplasma gondii: the model apicomplexan. Int. J. Parasitol. 2004, 34:423-432.
23. Lang C., Grob U., Luder C.G.K. Subversion of innate and adaptative immune responses by Toxoplasma gondii. Parasitol. Res. 2007, 100:191-203.
24. Martinez M., McDermott P., Walker R. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet. J. 2006, 172:10-28.
25. Martins-Duarte É.S., Lemgruber L., Lorente S.O., Gros L., Magaraci F., Gilbert I.H., De Souza W., Vommaro R.C. Evaluation of three novel azasterols against Toxoplasma gondii. Vet. Parasitol. 2011, 177:151-161.
26. Montoya J.G., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363:1965-1976.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
28. Neyer L.E., Grunig G., Fort M., Remington J.S., Rennick D., Hunter C.A. Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii. Infect. Immun. 1997, 65:1675-1682.
29. Oliveira T.C., Silva D.A.O., Rostkowsa C., Bela S.R., Ferro E.A.V., Magalhães P.M., Mineo J.R. Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo. Exp. Parasitol. 2009, 122:233-241.
30. Resende M.G., Fux B., Caetano B.C., Mendes E.A., Silva N.M., Ferreira A.M., Melo M.N., Vitor R.W., Gazzinelli R.T. The role of MHC haplotypes H2d/H2b in mouse resistance/susceptibility to cyst formation is influenced by the lineage of infective Toxoplasma gondii strain. An. Acad. Bras. Cienc. 2008, 80:85-99.
31. Schmidt D.R., Hogh B., Andersen O., Hansen S.T., Dalhoff K., Petersen E. Treatment of infants with congenital toxoplasmosis: tolerability plasma concentrations of sulfadiazine and pyrimethamine. Eur. J. Pediatr. 2006, 165:19-25.
32. Silva N.M., Manzan R.M., Carneiro W.P., Milanezi C.M., Silva J.S., Ferro E.A.V., Mineo J.R. Toxoplasma gondii: the severity of toxoplasmic encephalitis in C57BL/6 mice is associated with increased ALCAM and VCAM-1 expression in the central nervous system and higher blood-brain barrier permeability. Exp. Parasitol. 2010, 126:167-177.
33. Suzuki Y., Sher A., Yap G., Park D., Neyer L.E., Liesenfeld O., Fort M., Kang H., Gufwoli E. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J. Immunol. 2000, 164:5375-5382.
34. Willmott C.J., Critchlow S.E., Eperon I.C., Maxwell A. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J. Mol. Biol. 1994, 242:351-363.